Comparing OSR (OSRH) and The Competition

OSR (NASDAQ:OSRH) is one of 89 publicly-traded companies in the “UNCLASSIFIED” industry, but how does it weigh in compared to its rivals? We will compare OSR to similar businesses based on the strength of its risk, profitability, earnings, dividends, institutional ownership, valuation and analyst recommendations.

Institutional & Insider Ownership

55.3% of OSR shares are held by institutional investors. Comparatively, 52.0% of shares of all “UNCLASSIFIED” companies are held by institutional investors. 60.6% of OSR shares are held by insiders. Comparatively, 42.9% of shares of all “UNCLASSIFIED” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares OSR and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	N/A	-6.66%	-4.90%
OSR Competitors	0.86%	0.95%	0.80%

Volatility and Risk

OSR has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, OSR’s rivals have a beta of -0.09, suggesting that their average share price is 109% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for OSR and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
OSR Competitors	255	268	217	3	1.96

As a group, “UNCLASSIFIED” companies have a potential upside of 139.74%. Given OSR’s rivals stronger consensus rating and higher possible upside, analysts clearly believe OSR has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares OSR and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OSR	-$90,515.00	-$2.41 million	-0.50
OSR Competitors	$36.19 million	-$16.78 million	70.89

OSR’s rivals have higher revenue, but lower earnings than OSR. OSR is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

OSR rivals beat OSR on 9 of the 13 factors compared.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.